In the acute phase of stroke damage (1–7 days) following ischemia with reperfusion, we have previously demonstrated the Nox2 catalytic component to be the predominant Nox subtype that is upregulated and associated with phagocytic microglial cells, indicating this NADPH oxidase to be a potential target for therapeutic intervention [4]. This evidence concerns the gene FMO5 and stroke disorder.